norethindrone acetate has been researched along with Uterine Hemorrhage in 37 studies
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.
Uterine Hemorrhage: Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A group of 56 premenopausal women with non-atypical endometrial hyperplasia were enrolled and received: genistein aglycone (n=19; 54 mg/day); norethisterone acetate (n=19; 10 mg/day on days 16-25 of the menstrual cycle) or placebo (n=18) for 6 months." | 9.14 | Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. ( Adamo, EB; Altavilla, D; Bitto, A; D'Anna, R; Giordano, D; Granese, R; Maisano, D; Marini, H; Nicotina, PA; Squadrito, F; Triolo, O; Villari, D, 2010) |
| "To compare the incidence of vaginal spotting/bleeding events and breast pain between therapy with tibolone 2." | 5.14 | Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. ( Birkhaeuser, MH; Davis, S; Mulder, RJ; Nathorst-Böös, J; Nijland, EA; Palacios, S; Schultz, WC; Stathopoulos, VM; van de Weijer, PW; von Mauw, E, 2009) |
| "A group of 56 premenopausal women with non-atypical endometrial hyperplasia were enrolled and received: genistein aglycone (n=19; 54 mg/day); norethisterone acetate (n=19; 10 mg/day on days 16-25 of the menstrual cycle) or placebo (n=18) for 6 months." | 5.14 | Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. ( Adamo, EB; Altavilla, D; Bitto, A; D'Anna, R; Giordano, D; Granese, R; Maisano, D; Marini, H; Nicotina, PA; Squadrito, F; Triolo, O; Villari, D, 2010) |
| "To assess prospectively the effect on bleeding patterns, transformation of the endometrium, and rate of endometrial hyperplasia of transdermal norethisterone acetate when administered sequentially in combination with transdermal estradiol (E2), and to compare it to a regimen using oral medroxyprogesterone acetate." | 5.07 | Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. ( Boyd, ME; Colgan, TJ; Ferenczy, A; Fugere, P; Lorrain, J; Ross, AH, 1993) |
| " Adverse events occurring from the first trial-related activity, whether related or not related to the study medication, were recorded for the entire population (n = 575) of the trial." | 2.75 | Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results. ( Hruska, J; Samsioe, G, 2010) |
| "For the first 3 months, vaginal bleeding/spotting rate for the CEE/MPA group was 38." | 2.72 | Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. ( Eren, S; Pekin, O; Tugrul, S; Uslu, H; Yildirim, G, 2006) |
| "The incidence and duration of vaginal bleeding were assessed throughout the study." | 2.71 | Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. ( Liu, JH; Shumel, BS; Simon, JA; Speroff, L; Symons, JP, 2003) |
| " No adverse drug reactions specific to E2V/MPA triphasic were observed." | 2.71 | Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen. ( Engelstein, M; Kuhl, H; Mäenpää, J; Mattila, L; Mustonen, M; Rees, MC, 2004) |
| "After three treatment cycles body weight increased in both treatment groups by between 500 and 700 g." | 2.68 | Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. ( Lübbert, H; Nauert, C, 1997) |
| "Menorrhagia was treated with the "rollerball" method for five years, 1988-1993, in 200 patients." | 1.29 | "Rollerball" ablation of the endometrium. ( Paskowitz, RA, 1995) |
| " The pharmacokinetics and bioavailability of NET remain unchanged during early pregnancy." | 1.27 | Norethisterone acetate and ethinylestradiol in early human pregnancy. ( Düsterberg, B; Hasan, H; Kivikoski, A; Laajoki, V; Pulkkinen, MO, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (18.92) | 18.7374 |
| 1990's | 9 (24.32) | 18.2507 |
| 2000's | 17 (45.95) | 29.6817 |
| 2010's | 4 (10.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mattsson, LÅ | 3 |
| Ipsen, HE | 1 |
| Granqvist, CJ | 1 |
| Kokot-Kierepa, M | 1 |
| Huguelet, PS | 1 |
| Buyers, EM | 1 |
| Lange-Liss, JH | 1 |
| Scott, SM | 1 |
| Nijland, EA | 1 |
| Nathorst-Böös, J | 1 |
| Palacios, S | 1 |
| van de Weijer, PW | 1 |
| Davis, S | 1 |
| Stathopoulos, VM | 1 |
| Birkhaeuser, MH | 1 |
| von Mauw, E | 1 |
| Mulder, RJ | 1 |
| Schultz, WC | 1 |
| Samsioe, G | 2 |
| Hruska, J | 1 |
| Bitto, A | 1 |
| Granese, R | 1 |
| Triolo, O | 1 |
| Villari, D | 1 |
| Maisano, D | 1 |
| Giordano, D | 1 |
| Altavilla, D | 1 |
| Marini, H | 1 |
| Adamo, EB | 1 |
| Nicotina, PA | 1 |
| D'Anna, R | 1 |
| Squadrito, F | 1 |
| Simsek, T | 1 |
| Karakus, C | 1 |
| Trak, B | 1 |
| von Holst, T | 1 |
| Lang, E | 2 |
| Winkler, U | 1 |
| Keil, D | 1 |
| Simon, JA | 1 |
| Liu, JH | 1 |
| Speroff, L | 2 |
| Shumel, BS | 1 |
| Symons, JP | 1 |
| Rees, MC | 1 |
| Kuhl, H | 1 |
| Engelstein, M | 1 |
| Mattila, L | 1 |
| Mäenpää, J | 2 |
| Mustonen, M | 1 |
| Skouby, SO | 1 |
| Heikkinen, J | 1 |
| Vaheri, R | 2 |
| Timonen, U | 2 |
| Dahmoun, M | 1 |
| Odmark, IS | 1 |
| Risberg, B | 2 |
| Karlsson, MG | 1 |
| Pavlenko, T | 1 |
| Bäckström, T | 1 |
| Pornel, B | 2 |
| Spielmann, D | 3 |
| Koninckx, PR | 1 |
| Yildirim, G | 1 |
| Tugrul, S | 1 |
| Uslu, H | 1 |
| Pekin, O | 1 |
| Eren, S | 1 |
| Bouchard, P | 1 |
| De Cicco-Nardone, F | 1 |
| Garcea, N | 1 |
| Sturdee, DW | 1 |
| Archer, DF | 2 |
| Rakov, V | 1 |
| Flowers, CE | 1 |
| Wilborn, WH | 1 |
| Hyde, BM | 1 |
| Pulkkinen, MO | 1 |
| Düsterberg, B | 1 |
| Hasan, H | 1 |
| Kivikoski, A | 1 |
| Laajoki, V | 1 |
| Hardt, W | 1 |
| Schmidt-Gollwitzer, K | 1 |
| Nevinny-Stickel, J | 1 |
| Schmidt-Gollwitzer, M | 1 |
| Tokin, R | 1 |
| Dimov, I | 1 |
| Dzhebarov, S | 1 |
| Cullberg, G | 1 |
| Paskowitz, RA | 1 |
| Ross, AH | 1 |
| Boyd, ME | 1 |
| Colgan, TJ | 1 |
| Ferenczy, A | 1 |
| Fugere, P | 1 |
| Lorrain, J | 1 |
| Saure, A | 1 |
| Hirvonen, E | 2 |
| Milsom, I | 1 |
| Christensen, A | 1 |
| Damber, MG | 1 |
| Rozenberg, S | 2 |
| Ylikorkala, O | 2 |
| Arrenbrecht, S | 1 |
| Lübbert, H | 1 |
| Nauert, C | 1 |
| Dorin, MH | 1 |
| Heine, W | 1 |
| Nanavati, N | 1 |
| Arce, JC | 2 |
| Symons, J | 1 |
| Kempfert, N | 1 |
| Caubel, P | 1 |
| Lim, PC | 1 |
| Bruhat, M | 1 |
| Rudolf, K | 1 |
| Kainulainen, P | 1 |
| Viitanen, A | 1 |
| al-Azzawi, F | 1 |
| Wahab, M | 1 |
| Thompson, J | 1 |
| van der Mooren, MJ | 1 |
| Dillon, J | 1 |
| Magaril, C | 1 |
| Loh, FH | 1 |
| Chen, LH | 1 |
| Yu, SL | 1 |
| Jorgensen, LN | 1 |
| Baerug, U | 1 |
| Winge, T | 1 |
| Nordland, G | 1 |
| Faber-Swensson, E | 1 |
| Heldaas, K | 1 |
| Norling, B | 1 |
| Larsen, S | 1 |
| Hillard, TC | 1 |
| Siddle, NC | 1 |
| Whitehead, MI | 3 |
| Fraser, DI | 1 |
| Pryse-Davies, J | 3 |
| Lindgren, R | 1 |
| Hammar, M | 1 |
| Berg, G | 1 |
| Fraser, D | 1 |
| Padwick, ML | 1 |
| Endacott, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Six Month Double-blind, Randomised, Parallel-group, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of Two Ultra-low Dose Combinations With 0.5 mg Estradiol and 0.1 mg or 0.25 mg Norethisterone Acetate (Activelle Low Dose 0[NCT00184795] | Phase 3 | 576 participants (Actual) | Interventional | 2004-05-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for norethindrone acetate and Uterine Hemorrhage
| Article | Year |
|---|---|
The effects of estrogens and progestogens on the endometrium. Modern approach to treatment.
Topics: Drug Administration Schedule; Endometrium; Estrogens; Female; Humans; Menopause; Middle Aged; Noreth | 1987 |
26 trials available for norethindrone acetate and Uterine Hemorrhage
| Article | Year |
|---|---|
Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
Topics: Administration, Cutaneous; Aged; Breast; Double-Blind Method; Estradiol; Female; Humans; Middle Aged | 2009 |
Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
Topics: Blood Glucose; Blood Pressure; Breast; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; | 2010 |
Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia.
Topics: Adult; Contraceptives, Oral, Synthetic; Double-Blind Method; Endometrial Hyperplasia; Endometrium; F | 2010 |
Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; | 2002 |
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.
Topics: Adult; Aged; Austria; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Estra | 2002 |
Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Topics: Adult; Amenorrhea; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); E | 2003 |
Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen.
Topics: Adult; Aged; Biopsy; Climacteric; Contraceptive Agents, Female; Double-Blind Method; Endometrium; Es | 2004 |
A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen.
Topics: Aged; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2004 |
Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT.
Topics: Apoptosis; Biopsy; Cell Proliferation; Endometrium; Estradiol; Estrogen Receptor alpha; Estrogen Rep | 2004 |
A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Drug Combinations; E | 2005 |
A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.
Topics: Administration, Oral; Adult; Body Weight; Double-Blind Method; Drug Administration Schedule; Drug Co | 2005 |
Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Topics: Adult; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Con | 2006 |
Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women.
Topics: Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endometrium; Estradiol | 2005 |
Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women.
Topics: Adult; Aged; Amenorrhea; Contraceptives, Oral, Synthetic; Dose-Response Relationship, Drug; Double-B | 2008 |
Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Biopsy; Drug Therapy, Combination; Endometri | 1993 |
A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Topics: Administration, Oral; Climacteric; Desogestrel; Double-Blind Method; Endometrial Hyperplasia; Endome | 1996 |
Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Topics: Administration, Cutaneous; Administration, Oral; Cohort Studies; Estradiol; Estrogen Replacement The | 1997 |
Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Body Weight; Cohort Studies; Estradiol; Estr | 1997 |
Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; Female | 1999 |
Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators.
Topics: Adult; Aged; Climacteric; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogen Repl | 2000 |
Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms.
Topics: Adult; Aged; Drug Administration Schedule; Estradiol; Estrogen Replacement Therapy; Estrogens; Femal | 2001 |
Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therap | 2001 |
Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate.
Topics: Argentina; Double-Blind Method; Endometrium; Estradiol; Estrogen Replacement Therapy; Europe; Female | 2001 |
The efficacy of two dosages of a continuous combined hormone replacement regimen.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Asian People; Cholesterol; Cholesterol, HDL; Cholesterol, L | 2002 |
Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?
Topics: Estradiol; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Menopause; Middle Aged; Noreth | 1998 |
Endometrial effects of transdermal estradiol/norethisterone acetate.
Topics: Administration, Cutaneous; Adult; Aged; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Re | 1992 |
10 other studies available for norethindrone acetate and Uterine Hemorrhage
| Article | Year |
|---|---|
Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy.
Topics: Contraceptives, Oral, Synthetic; Estradiol; Estrogen Replacement Therapy; Female; Hot Flashes; Human | 2015 |
Treatment of Acute Abnormal Uterine Bleeding in Adolescents: What Are Providers Doing in Various Specialties?
Topics: Adolescent; Adolescent Medicine; Child; Contraceptives, Oral, Combined; Emergency Treatment; Female; | 2016 |
Mechanisms of uterine bleeding in postmenopausal patients receiving estrogen alone or with a progestin.
Topics: Adult; Drug Therapy, Combination; Endometrium; Estrogens, Conjugated (USP); Female; Histocytochemist | 1983 |
Norethisterone acetate and ethinylestradiol in early human pregnancy.
Topics: 17-alpha-Hydroxyprogesterone; Double-Blind Method; Estradiol; Ethinyl Estradiol; Female; Follicle St | 1984 |
[Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Topics: Adult; Buserelin; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Drug Evaluation; Endometriu | 1982 |
[Therapeutic potentials of treating uterine hemorrhages with norethisterone acetate].
Topics: Adolescent; Adult; Drug Evaluation; Female; Humans; Metrorrhagia; Middle Aged; Norethindrone; Noreth | 1983 |
Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints.
Topics: Climacteric; Estradiol; Female; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Uterine H | 1982 |
"Rollerball" ablation of the endometrium.
Topics: Electrocoagulation; Endometrium; Female; Humans; Hysterectomy; Leuprolide; Life Tables; Medroxyproge | 1995 |
Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis.
Topics: Amenorrhea; Atrophy; Drug Therapy, Combination; Endometrium; Estrogen Replacement Therapy; Female; H | 1992 |
Endometrial responses to transdermal estradiol in postmenopausal women.
Topics: Administration, Topical; Adult; Endometrium; Estradiol; Female; Humans; Menopause; Middle Aged; Nore | 1985 |